1. 184 Two types of anti-TIGIT antibodies with distinct binding epitope and functional activities. (9th November 2020) Authors: Zhong, Tingting; Pang, Xinghua; Huang, Zhaoliang; Chen, Na; Jin, Xiaoping; Xia, Yu; Wang, Maxwell Zhongmin; Li, Baiyong Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A109 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 384 A Phase 1 study to evaluate the safety, PK, and antitumor activity of AK117, an anti-CD47 monoclonal antibody, in subjects with relapsed/refractory advanced or metastatic solid tumors or lymphomas. (9th November 2020) Authors: Prawira, Amy; Coward, Jermaine; Mislang, Anna; Nagrial, Adnan; Gan, Hui; Jin, Xiaoping; Li, Baiyong; Wang, Zhongmin Maxwell; Kwek, Kon Yew; Xia, Dennis; Xia, Yu Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A409 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 384 A Phase 1 study to evaluate the safety, PK, and antitumor activity of AK117, an anti-CD47 monoclonal antibody, in subjects with relapsed/refractory advanced or metastatic solid tumors or lymphomas. (10th December 2020) Authors: Prawira, Amy; Coward, Jermaine; Mislang, Anna; Nagrial, Adnan; Gan, Hui; Jin, Xiaoping; Li, Baiyong; Wang, Zhongmin Maxwell; Kwek, Kon Yew; Xia, Dennis; Xia, Yu Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A233 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 476 AK119, a humanized anti-CD73 monoclonal antibody, as Immunotherapy for COVID-19. (9th November 2020) Authors: Zhong, Tingting; Huang, Zhaoliang; Pang, Xinghua; Chen, Na; Kwek, Konyew; Wynne, Chris; Konpa, Adam; Jin, Xiaoping; Xia, Yu; Wang, Maxwell Zhongmin; Li, Baiyong; Xia, Yu Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A508 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 476 AK119, a humanized anti-CD73 monoclonal antibody, as Immunotherapy for COVID-19. (9th November 2020) Authors: Zhong, Tingting; Huang, Zhaoliang; Pang, Xinghua; Chen, Na; Kwek, Konyew; Wynne, Chris; Konpa, Adam; Jin, Xiaoping; Xia, Yu; Wang, Maxwell Zhongmin; Li, Baiyong; Xia, Yu Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A292 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 702 Dual blockade of the PD-1 checkpoint pathway and the adenosinergic negative feedback signaling pathway with a PD-1/CD73 bispecific antibody for cancer immune therapy. (9th November 2020) Authors: Zhong, Tingting; Huang, Zhaoliang; Pang, Xinghua; Chen, Na; Jin, Xiaoping; Xia, Yu; Wang, Zhongmin Maxwell; Li, Baiyong; Xia, Yu Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A422 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 791 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with relapsed or refractory classic hodgkin lymphoma (cHL). (9th November 2020) Authors: Song, Yuqin; Zhou, Keshu; Jin, Chuan; Qian, Zhengzi; Hou, Ming; Fan, Lei; Li, Fei; Ding, Kaiyang; Zhou, Hui; Li, Xiaoling; Chen, Bing; Sun, Xiuhua; Song, Xianmin; Jiang, Ming; Zhang, Qingyuan; Liu, Lihong; Yu, Guohua; Hu, Yu; Zhao, Zheng; Liu, Ligen Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A840 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 804 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy. (9th November 2020) Authors: Chen, Xiaozhong; Wang, Wei; Zou, Qingfeng; Li, Jingao; Hu, Chaosu; Hu, Chaosu; Lin, Qin; Zhu, Xiaodong; Jiang, Yi; Sun, Yan; Shen, Liangfang; Wang, Lin; Zou, Guorong; Lin, Xiaoyan; Wang, Ying; Lin, Shaojun; Li, Minying; Ao, Rui; Xu, Ruilian; Lin, Haifeng Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A481 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity. Issue 1 (31st December 2023) Authors: Pang, Xinghua; Huang, Zhaoliang; Zhong, Tingting; Zhang, Peng; Wang, Zhongmin Maxwell; Xia, Michelle; Li, Baiyong Journal: MAbs Issue: Volume 15:Issue 1(2023) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity. Issue 11 (30th November 2022) Authors: Qu, Tailong; Zhong, Tingting; Pang, Xinghua; Huang, Zhaoliang; Jin, Chunshan; Wang, Zhongmin Maxwell; Li, Baiyong; Xia, Yu Journal: Journal for immunotherapy of cancer Issue: Volume 10:Issue 11(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗